The Narendra Modi government has taken a significant step to curb unethical practices in the pharmaceutical industry. In a move that breaks away from the previous voluntary status, the Department of Pharmaceuticals has made the new marketing code for pharma companies mandatory. This regulation aims to ensure transparency, accountability, and responsible conduct in the relationship between pharmaceutical companies and healthcare professionals.
The Uniform Code for Pharmaceuticals Marketing Practices (UCPMP)
The newly enforced marketing code, known as the Uniform Code for Pharmaceuticals Marketing Practices (UCPMP), outlines guidelines for interactions between pharmaceutical companies and doctors. Here are some key provisions:
No Gifts or Personal Benefits: The code explicitly states that “no gift should be offered or provided for the personal benefit of any healthcare professional or family member by any pharmaceutical company or its agent.” This means that travel perks, gifts, and other benefits are now strictly prohibited.
Government Oversight: The entire process is now under government oversight. Any government agency or authority can be involved as per relevant statutes and context. This move ensures that the code remains effective and accountable.
Penalties and Recommendations: The code includes provisions for penalties and references to government agencies. If any disciplinary, penal, or remedial action falls within the domain of a government agency, the UCPMP committee can send its recommendations through the Department of Pharmaceuticals.
Background and Catalyst
Prime Minister Narendra Modi initiated efforts to strengthen the UCPMP back in 2019. He warned India’s top pharmaceutical companies to strictly adhere to marketing ethics and avoid bribing doctors. The catalyst for this action was a report by the NGO Support for Advocacy and Training to Health (SATHI), which revealed that medical representatives (MRs) were offering bribes such as overseas trips, high-end smartphones, and gadgets to doctors.
A New Era of Accountability
From restricting the supply of free drug samples to limiting the use of healthcare professionals’ names or photographs in promotional material, the nine-page UCPMP covers all essential aspects of marketing and promotions. With this new era of accountability, the pharmaceutical industry is expected to operate with greater transparency and integrity.
As the government takes a firm stance against unethical practices, the focus shifts toward responsible marketing practices that prioritize patient welfare over commercial interests. The UCPMP aims to build trust between pharmaceutical companies and healthcare professionals, ultimately benefiting patients and the healthcare system as a whole.